



RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1614  
PATENT

Attorney Docket No. 61169

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Flack et al.

Serial No. 08/379,872

Filed: January 27, 1995

For: GOSSYPOL FOR THE TREATMENT  
OF CANCER

Group Art Unit: 1614


Examiner: J. Goldberg

AMENDMENT AFTER FINAL REJECTION

Assistant Commissioner for Patents  
Box AF  
Washington, D.C. 20231

Dear Sir:

In response to the final Office Action dated February 27, 1998, please enter the following amendments and consider the following remarks.



AMENDMENTS

IN THE CLAIMS:

Please amend claims 1 and 13 as follows:

1. (Thrice Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a physiologically acceptable salt of gossypol, gossypolone, a physiologically acceptable salt of gossypolone, or any combination thereof, which method comprises:  
administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol, a physiologically acceptable salt of gossypol, gossypolone, and a physiologically acceptable salt of

06/10/1998 PWILSON 00000013 121216 08379872

1 FC:115

110.00 CH

24/5/98